A DRUG THAT RECEIVES REGULATORY APPROVAL FOR COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA WOULD EARN A HIGHER PATIENT SHARE IN THE UNITED STATES THAN IN EUROPE

A Therapy’s Effect on Executive Function and Functional Capacity are the Attributes that Most Influence Psychiatrists’ Prescribing Habits, According to a New Report from Decision Resources

February 17, 2009–Waltham, Mass. -- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that if a drug were to receive formal regulatory approval for the treatment of cognitive impairment associated with schizophrenia (CIAS), such an agent could earn up to 50 percent patient share in the United States and up to 33 percent patient share in Europe, according to surveyed U.S. and European psychiatrists.

The new report entitled Cognitive Impairment Associated with Schizophrenia: Emerging Consensus Expected to Define a New Indication as Physicians Await the Launch of the First Approved Drug finds that a therapy's effect on executive function (reasoning and problem solving) and functional capacity (ability to manage daily tasks) are the attributes that most influences psychiatrists' prescribing decisions in CIAS. To date, no drugs are formally approved for CIAS and off-label treatment is sporadic. However, clinical data and the opinions of interviewed thought leaders indicate that the currently-available therapy, modafinil (Cephalon's Provigil), as well as emerging agents from Roche/Memory Pharmaceuticals, Allon Therapeutics, Cephalon and Merck could demonstrate advantages in treating CIAS when compared with donepezil (Eisai/Pfizer's Aricept, Bracco's Memac), the sales-leading agent in this virtually untapped market.

"In rare cases when psychiatrists elect to prescribe off-label therapy for CIAS, such as donepezil, their choice of treatment is based in large part on a drug's proven benefits in other indications in the hopes that CIAS patients will experience similar benefits," said Decision Resources Analyst Jonathan Searles. "However, thanks to evolving consensus about clinical trial design and the most promising drug targets in CIAS, a growing number of developers are investigating novel compounds for the treatment of this new indication."

About the Report
Cognitive Impairment Associated with Schizophrenia: Emerging Consensus Expected to Define a New Indication as Physicians Await the Launch of the First Approved Drug is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

###

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
 


For more information, contact:


Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com
 


Search Reports

Decision Resources Group brands include: